Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

aTYR Pharma Inc. ATYR

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$190,000
▼ 19.1% YoY
$-74.1M
$-62.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 190,000.00
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.2 · Net income -74.1
5M10M-30M-60M
20132016201920222025
Compound annual growth
−73.7%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2025 · Operating -40856.3% · Net ·
-20000%-40000%
201320192025
ROE
FY2025 · ROE -107.8%
-50%-100%
201320192025
Three returns, three denominators.

Each USD of equity lost 108 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -62.1
-25.0M-50.0M
201320192025

Total assetsUSD 93.0M
EquityUSD 67.5M
CashUSD 10.7M
Current ratio5.30×

Equity funds 73% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ATYR, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.00.00.00.00.00.0◌◌◌◌◌◌
Operating income $B−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.0◌−0.0◌◌◌
Net income $B−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
EPS, diluted $−0.80−0.86−0.94−1.60−1.77−1.77−7.03−16.11−26.13−2.44−3.03−29.69−28.39
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %−107.8−79.7−62.2−50.2−47.9−61.4−59.2−70.5−75.9−65.1———
Shares out B0.100.080.060.030.030.010.000.030.030.020.020.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 50 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. Six checks were skipped: EPS is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image